LAWRENCEVILLE, N.J., Oct. 15, 2015 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced that it will host a Research and Development (R&D) Day for investors and analysts on Tuesday, October 27, 2015. The event is scheduled to take place from 4:00 to 6:00 p.m. Eastern Time in New York City, and will be simultaneously streamed as a webcast.
The presentations will focus on the Company's research and development programs and will feature five leading experts in directed chemotherapies, immunotherapies and RNA- or DNA-based therapies, including:
- Donald Braun, Ph.D., Vice President of Clinical Research, Cancer Treatment Centers of America
- William Gerthoffer, Ph.D., Professor and Chair, Biochemistry and Molecular Biology, University of South Alabama
- Charles A. Leath, III, M.D., MSPH, Associate Professor, Gynecologic Oncology, The University of Alabama School of Medicine of UAB
- Bradley A. Maron, M.D., Assistant Professor of Medicine, Harvard Medical School
- Premal Thaker, M.D., MS, Associate Professor, Washington University in St. Louis
A live webcast of the presentations will be available on Celsion's website at http://investor.celsion.com/events.cfm beginning at approximately 4:15 p.m. Eastern Time. To ensure a timely connection, users should register at least 15 minutes prior to the scheduled start. The webcast will be archived for replay following the event for 90 days.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer. The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas™ and TheraSilence™. For more information on Celsion, visit our website: http://www.celsion.com.
Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data, particularly in small subgroups that are not statistically significant; FDA and regulatory uncertainties and risks; the significant expense, time, and risk of failure of conducting clinical trials; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion's periodic reports and prospectuses filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Celsion Investor Contact
Jeffrey W. Church
Senior Vice President and CFO
Celsion Media Contacts
Berry & Company
SOURCE Celsion Corporation